Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 16Gynecologic 10Gastrointestinal 9Tumor-Agnostic 6Genitourinary 6Other solid neoplasm 4Head & Neck 2CNS 2Breast 2Sarcoma 1Other hematologic neoplasm 1NET 1Endocrine 1Dermatologic 1

Conditions

Recurrence 1Oligodendroglioma 1Gliosarcoma 1Glioblastoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Radiotherapy 144Doxorubicin 112Temozolomide 110Cyclophosphamide 110Filgrastim 79Ifosfamide 70Imatinib Mesylate 69Etoposide 69Bevacizumab 55Vincristine 51Gemcitabine 50Peripheral Blood Stem Cell Transplantation 47Irinotecan 43Methotrexate 39Cisplatin 36Carboplatin 36Radiation 35fludarabine phosphate 34Busulfan 34pazopanib 32Sirolimus 30Melphalan 30Trabectedin 29Docetaxel 27Chemotherapy, Adjuvant 27Cyclosporine 25Carmustine 25sargramostim 24Surgical Procedures, Operative 23Sunitinib 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × nintedanib × Sarcoma × Clear all
NCT01380782 2014-08-18

BIBF 1120 for Recurrent High-Grade Gliomas

Dana-Farber Cancer Institute

Phase 2 Completed
37 enrolled 11 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Oligodendroglioma, Recurrence, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡